Review on GSTA1, with data on DNA/RNA, on the protein encoded and where the gene is implicated.
Crystal structure of human glutathione transferase (GST) A1-1 in complex with glutathione. Adapted from PDB (Grahn et al., 2006) .
Polymorphisms: GSTA1 has a functional three apparently linked single nucleotide polymorphisms (SNPs) in an SP1-responsive element within the proximal promoter (G-52A, C-69T and T-567G), plus at least four SNPs further upstream and a silent SNP A-375G. Two variants, GSTA1*A (-567T, -69C,-52G) and GSTA1*B (-67G, -69T, -52A), have been named according to the linked functional SNPs. Specifically, these substitutions result in differential expression with lower transcriptional activation of variant GSTA1*B than common GSTA1*A allele. It has been suggested that this genetic variation can change an individual's susceptibility to carcinogens and toxins, as well as, affect the efficacy of some drugs . In addition, the linkage disequilibrium between GSTA1*A/GSTA1*B and GSTA2G335C (Ser112Thr) has been shown in Caucasians: specifically, GSTA1*A/GSTA2C335 (Thr112) and GSTA1*B/GSTA2G335 (Ser112) (Ning et al., 2004) . It seems that the higher hepatic expression of GSTA1 enzyme in homozygous GSTA1 individuals is associated with the lower hepatic expression of GSTA2 in GSTA2C335 (Thr112) individuals (Coles et al., 2001a; Ning et al., 2004) . Other haplotypes within this nomenclature but including SNPs C-115T, T-631G, and C-1142G also have been proposed (Bredschneider et al., 2002; Guy et al., 2004) . Polymorphisms upstream of G-52C seem to have little effect on GSTA1 expression (Morel et al., 2002) .
Protein
Note Glutathione S-transferase A1 is N-terminally processed. Amino acids: 222. Calculated molecular mass: 25,63 kDa.
Description
The active GSTA1-1 enzyme is a homodimer, with each subunit containing a GSH-binding site (G-site) and a second adjacent hydrophobic binding site for the electrophilic substrate (H-site) (Wilce and Parker, 1994) . The C-terminal region of GSTA1-1 contributes to the catalytic and noncatalytic ligand-binding functions of the enzyme, while the conserved G-site is located in the N-terminal domain (Balogh et al., 2009) . Protein flexibility and dynamics in a molten globule-active site including the C-terminal α9 helix and the protruding ends of the α4-α5 helices result in achieving remarkable catalytic promiscuity of GSTA1-1 (Wu and Dong, 2012; Honaker et al., 2013) . It has been proposed that the α9 helix may function as a mobile gate to the active-site cavity, controlling substrate access and product release.
Structure determination and refinement of human alpha class glutathione transferase A1-1, and a comparison with the MU and PI class enzymes. Adapted from PDB (Sinning et al., 1993) .
Expression
GSTA1-1 is highly expressed (as mRNA and protein) in liver, intestine, kidney, adrenal gland, pancreas and testis, while expression in a wide range of tissues is low (Hayes and Pulford, 1995; Coles et al., 2001a) . Both positive and negative regulatory regions are present in the 5` noncoding region of GSTA1, including a polymorphic SP1-binding site within the proximal promoter. Binding of the transcription factor AP1 has been suggested as a common mechanism for up-regulation of GSTs (Hayes and Pulford, 1995) . The results of recent study also implied the role of a Kelch-like ECHassociated protein 1 (Keap1)-dependent signaling pathway for the induction of the constitutive GSTA1 expression during epithelial cell differentiation (Kusano et al., 2008) . Regarding GSH-dependent ∆ 5 -∆ 4 isomerase activity of this class of enzyme, it has been shown that steroidogenic factor 1 (SF-1) is involved in regulation of expression of GSTA genes (Matsumura et al., 2013) . Aberrant overexpression has been observed in various malignancies such as colorectal (Hengstler et al., 1998) and lung cancer (Carmichael et al., 1988) , while decrease in alpha class GSTs has been observed in stomach and liver tumors (Howie et al., 1990) . A detailed recent review on GSTA1 can be found in Wu and Dong, 2012 .
Localisation
Cytosolic.
Function
Human GSTA1-1 enzyme catalyzes the GSHdependent detoxification of electrophiles showing highly promiscuous substrate selectivity for many structurally unrelated chemicals, including environmental carcinogens (e.g. benzo(a)pyrene diol epoxides), several alkylating chemotherapeutic agents (such as busulfan, chlorambucil, melphalan, phosphoramide mustard, cyclophosphamide, thiotepa), as well as, steroids and products of lipid degradation. GSTA1-1 is the most highly expressed GST of the liver and could therefore, be critical for "systemic" detoxification of electrophilic xenobiotics including carcinogens and drugs (Coles and Kadlubar, 2005) . In addition to enzymatic detoxification, GSTA1 acts as modulator of mitogen-activated protein kinase (MAPK) signal transduction pathway via a mechanism involving protein-protein interactions. Namely, GSTA1 forms complexes with c-Jun Nterminal kinase (JNK), modifying JNK activation during cellular stress (Adnan et al., 2012) . Thus, it is possible that GSTA1 confer drug resistance by two distinct means: by direct inactivation (detoxification) of chemotherapeutic drugs and by acting as inhibitors of MAPK pathway.
Homology
The alpha class GSTs is showing strong intra-class sequence similarity (Balogh et al., 2009 ).
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Mutations
Germinal
None described so far.
Somatic
36 mutations (COSMIC): 26 substitution-missense, 4 substitution-nonsense, 5 substitution-coding silent, 1 unknown type.
Implicated in
Colorectal cancer
Note Regarding the role of GSTA1 polymorphism in the risk of colorectal cancer, the results of epidemiological studies are still inconclusive. Several studies showed that GSTA1*B genotype (low hepatic expression) is associated with increased susceptibility to colorectal cancer, which imply the possible inefficient hepatic detoxification of food-derived carcinogen metabolite N-acetoxyPhIP (Coles et al., 2001b; Sweeney et al., 2002) . In contrast, meta-analysis of Economopoulos representing the pooled analysis of four studies (1648 cases, 2039 controls) does not confer this association.
Breast cancer
Note
The role of GSTA1 polymorphism in breast cancer risk was mainly based on investigation on response to chemotherapeutic drugs in these patients. In breast cancer patients on cyclophosphamide containing chemotherapy carriers of GSTA1*B/*B genotype showed significantly reduced five years risk of death in comparison to GSTA1*A homozygous carriers. This association was likely caused by decreased detoxification of the therapeutic metabolites of cyclophosphamide in GSTA1*B/*B patients (Sweeney et al., 2003) .
Bladder cancer
Note Recent investigation indicates that the GSTA1-low activity genotype in combination with the GSTM1-null genotype significantly increases the risk of bladder cancer in smokers . In addition, it seems that GSTA1 polymorphism may influence vulnerability to oxidative DNA damage, thereby contributing to the malignant potential of transitional cell carcinoma .
Myeloid leukemia
Note Aberant overexpression of both GSTA1 and GSTA2 proteins was found in blast cells derived from acute myeloid leukemia patients, showing resistance to doxorubicin in vitro (Sargent et al., 1999) . In addition, GSTA1 and CYP39A1 (member of cytochrome P450 family) polymorphisms were found to be associated with pharmacokinetics of busulfan, which is used in preparative regimens prior to stem cell transplantation in pediatric patients (ten Brink et al., 2013) .
Prostate cancer
Note Genetic variants of GSTA1 and GSTT1 may modify prostate cancer risk, especially among smokers (Komiya et al., 2005) .
Asthma
Note
Genetic alterations in GST enzymes may influence the detoxification of environmental toxic substances in airway and increase the risk of asthma. Thus, it has been shown that subjects with at least one allele -69T in the GSTA1 genotype have an increased risk of asthma (Polimanti et al., 2010) .
